ASP2802

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ASP2802, covering 2025-10-28 to 2025-10-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas [Phase 1]